Average 370-Mile Travel Highlights Rare Melanoma Trial Barriers

By Amara Osei

“Rare registry participants who enrolled in a trial traveled an average of 370 miles, and this highlights the potential challenge of accessing both clinical trials and specialized care for patients,” Scales said. The finding comes from the first RARE Registry data report, presented by Jessica Scales, PhD, associate director of Rare Melanoma Research at the Melanoma Research Alliance (MRA).

The web-based, bidirectional and interactive registry enrolls patients with acral, mucosal and cutaneous melanoma. The 2026 report centers on more than 40 survey questions in four areas:

• Disease and treatment history
• Genetics
• Tumor biomarkers
• Quality of life

Scales reviewed clinical trial access and clinician involvement in presenting the report. Its analysis covers melanoma overall and each of the acral, mucosal and cutaneous subtypes, although the source summary gives no registry sample size, response rate or travel estimate by subtype or stage.

Because this is a descriptive registry report, it can identify reported access barriers and patient priorities. It cannot establish that a trial or another intervention improved survival or quality of life.

When should clinicians discuss trials?

Registry participants reported that clinicians raised clinical trials as a last resort. Scales noted, however, that some patients may qualify in the adjuvant (after-surgery) setting or for another trial following surgery.

Scales advised dermatologists and referring clinicians to explain how trials work, how to enroll, and each option’s potential benefits and limitations. The MRA provides webinars and frequently asked questions for clinicians to share with patients.

The organization also works with trial sponsors to verify whether eligibility criteria explicitly include rare melanoma subtypes. That step may prevent inadvertent exclusion, although sponsor confirmation remains more reliable than assuming that a broader melanoma label covers every subtype.

What does the 370-mile average establish?

Major academic centers serve as trial hubs, while registry participants are distributed throughout the United States and not always located near them. The average travel distance therefore quantifies a geographic barrier to trial participation and specialized care.

The MRA plans to examine the factors driving access, or the lack of it, to clinical trials. The current mean does not reveal which factors account for the distance or whether distance affected enrollment decisions or clinical outcomes.

How can clinicians strengthen the registry?

Clinicians can raise awareness of the RARE Registry and encourage eligible patients to participate. Scales argued that collective participation can strengthen the registry’s representation of rare melanoma, although the source provides no enrollment target or demographic benchmark for evaluating that claim.

She also asked clinicians to read the first report and propose additional surveys and research priorities. That step could direct future data collection toward questions patients and treating clinicians consider most consequential.

Three MRA initiatives may broaden research use:

• A data portal giving qualified researchers and clinicians access to aggregate, de-identified registry data.
• An electronic health record integration tool that allows participants to connect their medical records.
• The MRA Melanoma Biorepository, a direct-to-patient biobanking initiative for tissue collection.

The biorepository will send tumor and normal tissue samples from consenting patients to qualified researchers studying acral, cutaneous and mucosal melanoma. Scales said the initiative addresses the limited availability of biospecimens. Interested clinicians can email [email protected].

Those research tools remain dependent on participant consent, tissue availability and appropriate data governance. The source provides no projected sample volume, portal launch date or record-integration timeline.

How should quality of life influence melanoma care?

The report and an upcoming peer-reviewed study both address quality of life. Patients described effects on physical and mental well-being during and after treatment, extending the registry’s assessment beyond clinical endpoints alone.

That focus identifies outcomes relevant to daily life, but the source summary reports no effect sizes or comparative quality-of-life scores. The planned peer-reviewed study may provide more rigorous evidence for how treatment and disease burden affect patients.

“The patient voice is essential to improving how patients with all types of melanoma, whether common or rare, receive care throughout their disease journeys,” Scales said. She hopes dermatologists will weigh quality of life alongside clinical outcomes for every patient with melanoma.

She also hopes the report encourages a more personalized approach across all stages of disease. The MRA’s planned access analysis and upcoming peer-reviewed study will clarify whether earlier trial discussions and new data tools translate into more equitable melanoma care. Until those results appear, the 370-mile average identifies an unresolved access problem, not a tested solution.